ストックスクリーナーアプリを入手
47.47
1.07%
-0.6549
Moderna Inc (MRNA) 最新ニュース
CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewswire Inc.
Moderna, Inc. Trade Ideas — LSX:A2N9D9 - TradingView
Moderna stock (US60770K1034): Hantavirus headlines, Q1 revenue beat and lingering volatility - AD HOC NEWS
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform - BioSpace
Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain - TradingView
ROIV: Strong clinical progress and a $2.25B Moderna settlement drive robust financial position - TradingView
CHINA SHOTO : 15000 Leverage Shares 3x Long Moderna (MRNA) ETP Securities - marketscreener.com
Moderna Inc. stock (US60770K1034): FDA path, vaccine sales and pipeline updates in focus - AD HOC NEWS
2 Healthcare Stocks Worth Investigating and 1 Facing Headwinds - The Globe and Mail
Moderna’s SWOT analysis: biotech stock faces profitability test - Investing.com
Invesco S&P 500 Equal Weight Income Advantage ETF's Moderna Inc(MRNA) Holding History - GuruFocus
Transcript : Moderna, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 10 - marketscreener.com
MRNA: International partnerships and new vaccines fuel growth amid strong clinical and regulatory progress - TradingView
Moderna Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Moderna stock (US60770K1034): Insider sale adds to a volatile setup - AD HOC NEWS
Moderna president Stephen Hoge sells $2.58m in shares - Investing.com
Moderna (MRNA) president sells 53,336 shares after option exercises - Stock Titan
HHS rescinds vaccine panel charter citing 'administrative error' - Seeking Alpha
Moderna's revenues see strong international momentum in Q1 earnings - MSN
Moderna Inc. stock (US60770K1034): Shares slip as post-COVID reset keeps volatility high - AD HOC NEWS
Moderna, Inc. (MRNA): Navigating a Complex Landscape with Potential Growth in Biotechnology - DirectorsTalk Interviews
Moderna stock (US60770K1034): Shares slide as COVID-era sales reset remains in focus - AD HOC NEWS
Moderna Inc stock (US60770K1079): FDA review, vaccine pipeline and cash burn stay in focus - AD HOC NEWS
Moderna | History, Innovation, Challenges, & Facts - Britannica
Assessing Moderna (MRNA) Valuation After Flu Vaccine Trial Success And Hantavirus Research Attention - Yahoo Finance
Moderna, Inc. - TradingView
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 23,550 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Inc stock (US60770K1079): pipeline momentum and volatile share price keep investors on edge - AD HOC NEWS
MRNA Stock Quote Price and Forecast - CNN
Hantavirus: Is there a risk of another pandemic? - Investing.com
Moderna Recognized by TIME as One of the World's Most Impactful Companies - ACCESS Newswire
Moderna, Inc. (MRNA): Stock Analysis | Is It A Buy? | Feb 2025 | Trending Investment Insights (a6zSgQ1FJr) - fathomjournal.org
Moderna stock (US60770K1034): pipeline hopes meet volatile share price - AD HOC NEWS
Moderna (MRNA) Rule 144 notice: 53,336 shares proposed via Fidelity on 05/15/2026 - Stock Titan
Moderna stock (US60770K1034): focus on vaccine pipeline after latest earnings - AD HOC NEWS
Moderna Inc (MRNA:NSD) Sell The Strength As Stock Jumps On Trial Results (E66AVda6nQ) - fathomjournal.org
Moderna shares jump as it reveals it has been researching vaccines against hantaviruses - AOL.com
Moderna stock (US60770K1079): Shares up 71% YTD amid biotech volatility - AD HOC NEWS
Salesforce (CRM), Moderna Partner to Unify Global Operations via Agentforce Life Sciences - Yahoo Finance
Moderna stock (US60770K1034): Q1 2026 net income swings to $169.7M profit - AD HOC NEWS
Moderna stock (US60770K1034): Ranked #1 on TIME's 2026 Most Impactful Companies - AD HOC NEWS
Still ‘many steps to do’ in creating a hantavirus vaccine, experts say - Global News
Stock market today: S&P 500, Dow futures fall as Trump rejects 'totally unacceptable' Iran peace proposal—Micron Technologies, Moderna in focus - MSN
Moderna stock (US60770K1034): Gains 0.74% to $53.27 on May 12 - AD HOC NEWS
Arbutus Biopharma Q1 revenue surges on Moderna settlement - TradingView
Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit - Stock Titan
Moderna Is a Money-Losing Vaccine Maker. It’s Also the Ultimate Stock Hedge. - Barron's
Whitefort Capital Management, LP's Moderna Inc(MRNA) Holding History - GuruFocus
Money-Losing Moderna Is a Pandemic Hedge. What to Do With the Stock Now. - Barron's
Moderna (MRNA) Shares Skyrocket, What You Need To Know - Yahoo Finance
Transcript : Moderna, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 11 - marketscreener.com
Biotech Stocks Sway Amid Hantavirus Cruise Scare - Investing News Network
Moderna (MRNA) Targets August FDA Decision as mRNA Flu Vaccine Clears Phase 3 Efficacy Bar - AlphaStreet
Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell (NASDAQ:MRNA) - Seeking Alpha
Moderna's Revenues See Strong International Momentum in Q1 Earnings - TradingView
Moderna Inc. stock (US60770K1034): Jumps 8% on hantavirus hype, Q1 earnings beat - AD HOC NEWS
Moderna Updates Bylaws and Confirms Governance Leadership - The Globe and Mail
MODERNA : Jefferies reiterates its Neutral rating - marketscreener.com
Hantavirus outbreak: these 3 stocks are poised to rip higher - Invezz
Hantavirus Fears Fuel Moderna Rally: Is This a Real Catalyst or Just Sentiment? - NAI500
5 Insightful Analyst Questions From Moderna’s Q1 Earnings Call - Yahoo Finance
Moderna reports Q1 loss, stock jumps on strong international sales - MSN
0.06%
0.47%
大文字化:
|
ボリューム (24 時間):